Episode 04: Toward in silico Lead Discovery – the Advent of AI and Machine Learning w/ Lars Linden, PhD, Head, Protein Biochemistry, Biologics Research, Bayer

Dr. Lars Linden will be presenting during the Optimisation & Developability conference at PEGS Europe Summit, November 18-22, in Lisbon, Portugal. He speaks with CHI on August 6, 2019 to share his current responsibilities and how they have and will continue to evolve, especially with AI and machine learning in the horizon.Topics discussed include how developability assessments, combined with in silico assays and in vitro high throughput methods, are able to rank candidates quickly in discovery, to advance the best ones to lead optimization and help select the right molecules. This is especially useful with today’s myriad molecules from bi- to multi-specifics to different types of conjugates. Dr Linden further discusses the role and impact of AI and machine learning to accelerate and simplify drug discovery, and better predict and optimise molecules throughout the R&D value chain.